Premium
Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma
Author(s) -
Jo Masayasu,
Yasui Kohichiroh,
Kirishima Toshihiko,
Shima Toshihide,
Niimi Toshihisa,
Katayama Takayuki,
Mori Takahiro,
Funaki Jun,
Sumida Yoshio,
Fujii Hideki,
Takami Shiro,
Kimura Hiroyuki,
Mitsumoto Yasuhide,
Minami Masahito,
Yamaguchi Kanji,
Yoshinami Naomi,
Mizuno Masayuki,
Sendo Rei,
Tanaka Saiyu,
Shintani Hiroyuki,
Kagawa Keizo,
Okanoue Takeshi,
Itoh Yoshito
Publication year - 2014
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12308
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , propensity score matching , cohort , adverse effect , retrospective cohort study , cohort study , surgery
Aim Sorafenib is the standard systemic therapy for patients with advanced hepatocellular carcinoma ( HCC ). We aimed to assess the efficacy and safety of sorafenib therapy in very elderly patients aged 80 years and older with advanced HCC . Methods In a retrospective multicenter study in J apan, we reviewed 185 patients (median age, 71 years; 82% male; 95% Child–Pugh class A) with advanced HCC who received sorafenib therapy. Data were compared between 24 (13%) patients aged 80 years and older and 161 (87%) patients aged less than 80 years. We used propensity score matching to adjust for differences between the two groups. Results Median overall survival was 10.6 months in all patients: 11.7 months in patients aged 80 years and older and 10.5 months in those aged less than 80 years. There were no significant differences in overall survival, tumor response, and frequency and severity of drug‐related adverse events between patients aged 80 years and older and those aged less than 80 years in both the entire study cohort and the propensity‐matched cohort. Conclusion Sorafenib may be effective and well tolerated, even in patients with advanced HCC who are aged 80 years and older, as well as those aged less than 80 years.